Project description
Better diagnose, prevention and treatment
More than 60 million Europeans suffer from anxiety and depression or fibromyalgia and chronic fatigue syndrome. These conditions (comorbidities) are common in Irritable bowel syndrome (IBS) which is a chronic health condition experienced mainly by women. IBS creates a burden on the patients' life. But the origin and mechanisms of IBS comorbidities remain unexplained, treatment is costly and not satisfactory. The EU-funded DISCOvERIE project will make an effort to explain the causative mechanisms of IBS comorbidities, identify them as a distinct clinical entity to enable a significant improvement in its treatment methods. The specific comorbid-IBS psychopathological knowledge will allow delivery of prognostic biomarkers and creation of guides and protocols for new special hospital units providing personalised care.
Objective
Mental (anxiety and depression) and non-mental (fibromyalgia and chronic fatigue syndrome) comorbidities are highly prevalent in irritable bowel syndrome (IBS), with over 60 million Europeans affected, mostly women, by devastating manifestations, impaired treatment and quality of life. Estimated costs are €43 billion/year for IBS, mostly derived from comorbid IBS. Our hypothesis is that comorbid IBS represents a distinct clinical entity, arising from distorted brain-gut communication with a unique, specific, but undefined pathophysiological origin, differing from IBS alone. DISCOvERIE was created to advance the understanding of its causative mechanisms. Identification, validation and comprehension of these mechanisms will help stratify these patients into distinct clinical phenotypes, improving disease management, increasing quality of life and reducing socioeconomic costs. In particular, we will deliver specific comorbid-IBS physiopathological knowledge as clinical guides and protocols for newly created, hospital-based, transversal and multidisciplinary units for implementing personalized management and wellbeing of European citizens and to position Europe as a global leader in comorbid IBS personalised medicine. We will also deliver prognostic and therapeutic biomarkers and patents, technological innovation via e-health tools for personalized assessment of clinical/nutritional/physical activity and disseminate new knowledge widely. Impact will be assessed by recording media presence, scientific publications and by monitoring health-related quality of life of patients and promoting cost-effective care. To this end we have created a user board involving patient associations, clinical specialists, European healthcare experts, large pharma and SMEs representatives. We will also promote the creation of a European Reference Network for comorbid IBS involving healthcare providers across Europe.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
08035 Barcelona
Spain
See on map
Participants (20)
405 30 Goeteborg
See on map
Participation ended
6525 XZ Nijmegen
See on map
T12 YN60 Cork
See on map
60323 Frankfurt Am Main
See on map
3000 Leuven
See on map
69120 Heidelberg
See on map
40126 Bologna
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
40138 Bologna
See on map
9052 ZWIJNAARDE - GENT
See on map
6200 MD Maastricht
See on map
1085 Budapest
See on map
400012 Cluj-Napoca
See on map
08007 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
5405 PB Uden
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1180 Wien
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
98109 Seattle
See on map
08012 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
08028 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
08301 Mataro
See on map
6525 GA Nijmegen
See on map